Shrink Nanotechnologies, Inc. (“Shrink”) (OTCBB: INKN), an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that it is entering the final phase of its commercialization program for its first cell culturing devices for the StemDisc family of stem cell culturing products.
Within the last week, Shrink has received the final mold for the initial StemDisc product line. The balance of the design parameters have been completed, and the Company will begin building and testing the prototype commercial iterations of the StemDisc 450, which has been designed to allow biologists and researchers to culture HESCs (human embryonic stem cells) as well as IPSCs (induced pluripotent stem cells) with amazing simplicity, in an advantageous form factor and at a much lower cost. Shrink expects to begin to offer the product sometime in the 4th quarter of this year.
Commenting on this news, Shrink CEO and founder Mark L. Baum stated, “When we began the development of this product, we saw an opening in a sizable and growing market, provided we were able to offer a product that was superior in performance, cost and ease of use relative to the current available systems for growing EBs (embryoid bodies) and IPSCs. Now that we are nearing the final phase of the design and commercial prototyping stage, we believe we will have met and exceeded what we thought we would be able to do. We intend to debut images of the final designs as well as the initial prototype product this month.”